Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01951742Phase 2Completed

Dose Finding Study In Subjects With Crow's Feet

Role: lead

NCT01809964Phase 2Completed

Clinical Trial to Evaluate ANT-1401 in Crow's Feet

Role: lead

NCT01799824Phase 2Completed

Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis

Role: lead

NCT01293552Phase 2Completed

Clinical Trial To Evaluate ANT-1207 In Subjects With Acne

Role: lead

NCT01358695Phase 2Completed

Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet

Role: lead

All 5 trials loaded